UK Could Block Activist Plans To Shake Up GSK
New Law Allows Intervention
GlaxoSmithKline is under attack from an activist investor, but as a key UK company, the government could use new powers to block any deals “not in the national interest”.
You may also be interested in...
Cash-rich private equity firms are eyeing opportunities in healthcare, especially among listed companies with sluggish share prices. The Carlyle Group could be getting a bargain if it seals a deal for the Chippenham-based inhalation specialist.
Key investors have pledged more patience in CEO Walmsley’s turnaround but they will be expecting a convincing vision of the future, more dynamic, GSK.
TG Therapeutics is confident its late-stage candidate can take a slice of the multiple sclerosis market away from Roche’s blockbuster.